Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q1

2784.TEDINET S100RN02
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥709.1bn2023-04-01 → 2023-06-30Cons.Net sales
Revenue¥2.70T2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥657.1bn2022-04-01 → 2022-06-30Cons.Net sales
Operating income¥5.8bn2023-04-01 → 2023-06-30Cons.Operating income
Operating income¥3.1bn2022-04-01 → 2022-06-30Cons.Operating income
Ordinary income¥6.4bn2023-04-01 → 2023-06-30Cons.Ordinary income
Ordinary income¥32.8bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.7bn2022-04-01 → 2022-06-30Cons.Ordinary income
Profit before tax¥6.4bn2023-04-01 → 2023-06-30Cons.Income before income taxes
Profit before tax¥3.6bn2022-04-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)¥4.0bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥25.8bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.1bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income¥4.1bn2023-04-01 → 2023-06-30Cons.Profit loss
Net income¥2.2bn2022-04-01 → 2022-06-30Cons.Profit loss
Total assets¥1.39Tat 2023-06-30Cons.Assets
Total assets¥1.34Tat 2023-03-31Cons.Assets
Total assets¥1.33Tat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥909.2bnat 2023-06-30Cons.Liabilities
Total liabilities¥851.5bnat 2023-03-31Cons.Liabilities
Net assets / equity¥479.9bnat 2023-06-30Cons.Net assets
Net assets / equity¥488.3bnat 2023-03-31Cons.Net assets
Net assets / equity¥475.5bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥169.4bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥160.1bnat 2023-03-31Cons.Cash and deposits
EPS (basic)¥20.152023-04-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥127.422022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥10.52022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio34.5%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio35.8%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥8.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥8.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30¥129m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥631.6bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥626.8bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥4.8bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥5.3bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥12.3bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥3.5bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2023-04-01 → 2023-06-30−¥442m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥8.9bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥8.9bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥82m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2023-04-01 → 2023-06-30¥64.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2023-04-01 → 2023-06-30¥64.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥153m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2023-04-01 → 2023-06-30¥770m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-06-30¥717.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-06-30¥709.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-06-30¥8.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-06-30¥5.7bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥7.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30¥82m
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥585.4bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥580.9bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4.5bn
jpcrp040300-q1r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥2.4bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥11.0bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥7.9bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥3.1bn
jpcrp040300-q1r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥207m
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥8.8bn
jpcrp040300-q1r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-06-30−¥92m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥59.6bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥59.5bn
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥142m
jpcrp040300-q1r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥448m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-06-30¥664.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-06-30¥657.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-06-30¥7.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-06-30¥3.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 371
ItemContextValueUnit
Net assetsCurrentQuarterInstant479925000000JPY
Liabilities and net assetsPrior1YearInstant1339852000000JPY
Liabilities and net assetsCurrentQuarterInstant1389140000000JPY
Net salesPrior1YTDDuration657122000000JPY
Net salesCurrentYTDDuration709056000000JPY
Cost of salesPrior1YTDDuration614629000000JPY
Cost of salesCurrentYTDDuration661241000000JPY
Gross profitPrior1YTDDuration42493000000JPY
Gross profitCurrentYTDDuration47815000000JPY
Selling general and administrative expensesPrior1YTDDuration39404000000JPY
Selling general and administrative expensesCurrentYTDDuration41979000000JPY
Operating incomePrior1YTDDuration3088000000JPY
Operating incomeCurrentYTDDuration5835000000JPY
Interest income noiPrior1YTDDuration10000000JPY
Interest income noiCurrentYTDDuration11000000JPY
Dividends income noiPrior1YTDDuration362000000JPY
Dividends income noiCurrentYTDDuration373000000JPY
Real estate rent noiPrior1YTDDuration155000000JPY
Real estate rent noiCurrentYTDDuration136000000JPY
Other noiPrior1YTDDuration184000000JPY
Other noiCurrentYTDDuration185000000JPY
Non operating incomePrior1YTDDuration713000000JPY
Non operating incomeCurrentYTDDuration707000000JPY
Interest expenses noePrior1YTDDuration17000000JPY
Interest expenses noeCurrentYTDDuration15000000JPY
Commission fee noePrior1YTDDuration－JPY
Commission fee noeCurrentYTDDuration25000000JPY
Rent expenses on real estates noePrior1YTDDuration47000000JPY
Rent expenses on real estates noeCurrentYTDDuration44000000JPY
Other noePrior1YTDDuration30000000JPY
Other noeCurrentYTDDuration39000000JPY
Non operating expensesPrior1YTDDuration95000000JPY
Non operating expensesCurrentYTDDuration124000000JPY
Ordinary incomePrior1YTDDuration3706000000JPY
Ordinary incomeCurrentYTDDuration6418000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration0JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration6000000JPY
Extraordinary incomePrior1YTDDuration0JPY
Extraordinary incomeCurrentYTDDuration6000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration2000000JPY
Loss on sales of noncurrent assets elCurrentYTDDuration5000000JPY
Loss on retirement of noncurrent assets elPrior1YTDDuration22000000JPY
Loss on retirement of noncurrent assets elCurrentYTDDuration34000000JPY
Impairment loss elPrior1YTDDuration1000000JPY
Impairment loss elCurrentYTDDuration4000000JPY
Loss on valuation of investment securities elPrior1YTDDuration104000000JPY
Loss on valuation of investment securities elCurrentYTDDuration0JPY
Other elPrior1YTDDuration5000000JPY
Other elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration136000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass